Physician profile
Tess Pollinger
NPI 1598020273
$6,029.61
in general payments reported to CMS, 2019-2025
22 companies · $391 in 2025
The $391 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $586 · 2020: $286 · 2021: $775 · 2022: $1,576 · 2023: $1,039 · 2024: $1,376 · 2025: $391.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,531 · Education: $276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,530.59 |
| Education | $275.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,780.64 | 2019-2025 | |
| Janssen Biotech, INC. | $1,602.54 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Sun Pharmaceutical Industries INC. | $366.49 | 2021-2024 | Ilumya, Winlevi, Absorica Ld |
| Regeneron Healthcare Solutions, INC. | $322.29 | 2019-2025 | Dupixent, Libtayo |
| Incyte Corporation | $275.02 | 2022-2025 | Opzelura, Opzelura |
| Novartis Pharmaceuticals Corporation | $195.30 | 2019-2025 | |
| Celgene Corporation | $191.89 | 2019 | |
| Lilly USA, LLC | $183.72 | 2019-2024 | Taltz |
| Pfizer INC. | $136.09 | 2020-2024 | |
| Genzyme Corporation | $124.48 | 2020-2024 | |
| Janssen Scientific Affairs, LLC | $120.65 | 2022 | |
| Leo Pharma INC. | $117.10 | 2023-2025 | Adbry |
| Amgen INC. | $112.09 | 2019-2024 | Otezla |
| Galderma Laboratories, L.P. | $87.02 | 2020-2025 | Nemluvio |
| E.R. Squibb & Sons, L.L.C. | $81.86 | 2022-2023 | Sotyktu |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $80.40 | 2023-2024 | Cimzia, Bimzelx |
| Arcutis Biotherapeutics, INC. | $68.33 | 2023-2025 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $60.66 | 2019-2024 | Duobrii, Siliq |
| Dermavant Sciences, INC. | $43.92 | 2023-2024 | Vtama |
| Genentech USA, INC. | $31.85 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.14 | 2024 | Spevigo |
| Merz North America, INC. | $20.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tess Pollinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.